Septerna (NASDAQ:SEPN) SVP Sells $126,087.39 in Stock

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of Septerna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $37.83, for a total transaction of $126,087.39. Following the completion of the sale, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,647,265.96. This represents a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Septerna Stock Down 0.1%

SEPN opened at $36.75 on Friday. Septerna, Inc. has a twelve month low of $13.67 and a twelve month high of $51.10. The company’s 50-day moving average price is $37.44 and its two-hundred day moving average price is $31.19. The stock has a market cap of $1.72 billion, a price-to-earnings ratio of -68.06 and a beta of 2.30.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The company had revenue of $26.75 million during the quarter, compared to analyst estimates of $19.22 million. As a group, sell-side analysts anticipate that Septerna, Inc. will post -1.41 earnings per share for the current year.

Analysts Set New Price Targets

SEPN has been the topic of a number of recent research reports. Wells Fargo & Company upped their price target on Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Guggenheim boosted their price objective on Septerna from $45.00 to $51.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $49.00 price objective on shares of Septerna in a report on Tuesday, August 11th. Truist Financial increased their target price on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Finally, Stifel Nicolaus set a $49.00 target price on shares of Septerna in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.44.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SEPN. Woodline Partners LP increased its position in shares of Septerna by 94.2% during the first quarter. Woodline Partners LP now owns 582,585 shares of the company’s stock valued at $3,373,000 after buying an additional 282,585 shares during the period. Rhumbline Advisers boosted its position in shares of Septerna by 16.6% in the first quarter. Rhumbline Advisers now owns 23,318 shares of the company’s stock valued at $135,000 after acquiring an additional 3,323 shares during the period. Geode Capital Management LLC grew its stake in Septerna by 19.1% during the second quarter. Geode Capital Management LLC now owns 487,956 shares of the company’s stock valued at $5,158,000 after acquiring an additional 78,316 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares in the last quarter. Finally, CW Advisors LLC bought a new stake in Septerna during the 2nd quarter worth approximately $133,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.